Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $5.57 Consensus PT from Analysts

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) have been given an average rating of “Moderate Buy” by the eight ratings firms that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $5.57.

MRSN has been the subject of several recent analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $4.00 target price (down from $7.00) on shares of Mersana Therapeutics in a research note on Friday, January 10th. Citigroup assumed coverage on Mersana Therapeutics in a report on Friday, November 15th. They issued a “buy” rating and a $5.00 price target for the company.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of MRSN. Jacobs Levy Equity Management Inc. raised its stake in shares of Mersana Therapeutics by 104.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 993,046 shares of the company’s stock valued at $1,877,000 after acquiring an additional 507,453 shares during the period. State Street Corp raised its stake in shares of Mersana Therapeutics by 1.6% during the third quarter. State Street Corp now owns 2,725,394 shares of the company’s stock valued at $5,151,000 after purchasing an additional 43,339 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Mersana Therapeutics by 18.9% in the third quarter. JPMorgan Chase & Co. now owns 2,351,359 shares of the company’s stock valued at $4,444,000 after purchasing an additional 374,460 shares during the period. XTX Topco Ltd increased its stake in Mersana Therapeutics by 186.0% during the 3rd quarter. XTX Topco Ltd now owns 347,255 shares of the company’s stock worth $656,000 after buying an additional 225,823 shares during the period. Finally, Barclays PLC increased its stake in Mersana Therapeutics by 32.7% during the 3rd quarter. Barclays PLC now owns 494,516 shares of the company’s stock worth $934,000 after buying an additional 121,799 shares during the period. Hedge funds and other institutional investors own 93.92% of the company’s stock.

Mersana Therapeutics Price Performance

Shares of NASDAQ:MRSN opened at $0.64 on Wednesday. Mersana Therapeutics has a one year low of $0.49 and a one year high of $6.28. The stock has a market cap of $79.47 million, a PE ratio of -1.05 and a beta of 1.43. The business’s fifty day moving average price is $1.63 and its two-hundred day moving average price is $1.79. The company has a debt-to-equity ratio of 13.35, a quick ratio of 2.35 and a current ratio of 2.35.

Mersana Therapeutics (NASDAQ:MRSN) last released its earnings results on Wednesday, November 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.08. The company had revenue of $12.60 million for the quarter, compared to analyst estimates of $7.53 million. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The firm’s quarterly revenue was up 63.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.35) EPS. On average, analysts forecast that Mersana Therapeutics will post -0.61 EPS for the current fiscal year.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.